Literature DB >> 20650541

A different TRAP220 expression in distinct histologic subtypes of lung adenocarcinoma and the prognostic significance.

Jeanho Yun1, Choon Hee Son, Soo Jung Um, Hyuk Chan Kwon, Kyung Eun Lee, Phil Jo Choi, Mee Sook Roh.   

Abstract

Adenocarcinomas are a very heterogeneous subgroup of lung cancers, in which oncogenesis is linked to different molecular events. Recent evidence suggests that the hormonal status may contribute to the pathogenesis of lung adenocarcinoma. TRAP220 is the main subunit of the TRAP/Mediator complex and it binds to nuclear hormone receptors in the presence of their cognate ligand, as a cofactor of the transcription machinery. Since TRAP220 is an essential coactivator that interacts directly with estrogen receptor β (ERβ), we examined the expression of TRAP220 protein to investigate its role in lung adenocarcinoma, with particular attention being paid to its different histologic subtypes and the ERβ expression. We performed immunohistochemical detection of TRAP220 and ERβ protein in eighty-seven tissue samples from lung adenocarcinoma patients by using a tissue microarray, and Western blotting was then done to confirm the immunohistochemical observations. TRAP220 immunoreactivity was observed in 27 (31.0%) of the 87 adenocarcinoma cases. Analysis of the TRAP220 expression by Western blotting confirmed the immunohistochemical results. The TRAP220 expression was more frequently positive in the non-solid subtypes (bronchioloalveolar, acinar, and papillary patterns) than that in the solid subtype (P=0.027) and the TRAP220 expression was more frequently positive in the well-differentiated adenocarcinomas than that in the moderately or poorly differentiated adenocarcinomas (P=0.005). The tumors with a negative TRAP220 expression were larger in size (P=0.048) and they more frequently showed lymph node metastasis (P=0.002), pleural invasion (P=0.026) and an advanced TNM stage (P=0.012). The frequency of the TRAP220 expression in the cases with an ERβ expression was significantly higher than that in those cases without an ERβ expression (P=0.003). The Kaplan-Meier survival curves demonstrated that the patients with a positive TRAP220 expression had a significantly longer survival time than those patients with a negative TRAP220 expression (P=0.014). The multivariate analysis revealed that a TRAP220 expression was an independent good prognostic factor (P=0.049). Our data may be useful to understand the different biologic basis for the development and progression of the subtypes of lung adenocarcinoma.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650541     DOI: 10.1016/j.lungcan.2010.06.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

Review 1.  Mediator and human disease.

Authors:  Jason M Spaeth; Nam Hee Kim; Thomas G Boyer
Journal:  Semin Cell Dev Biol       Date:  2011-08-04       Impact factor: 7.727

2.  Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC.

Authors:  Liangan Chen; Zhixin Liang; Qing Tian; Chunsun Li; Xiuqing Ma; Yu Zhang; Zhen Yang; Ping Wang; Yanqin Li
Journal:  J Exp Clin Cancer Res       Date:  2011-02-09

3.  Naked cuticle Drosophila 1 expression in histologic subtypes of small adenocarcinoma of the lung.

Authors:  Sangjeong Ahn; Won Hwangbo; Hyunchul Kim; Chul Hwan Kim
Journal:  Korean J Pathol       Date:  2013-06-25

4.  Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer.

Authors:  Kyung A Kwon; Jeanho Yun; Sung Yong Oh; Bong-Gun Seo; Suee Lee; Ji-Hyun Lee; Sung-Hyun Kim; Hong Jo Choi; Mee Sook Roh; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2015-06-23       Impact factor: 4.679

5.  MED10 Drives the Oncogenicity and Refractory Phenotype of Bladder Urothelial Carcinoma Through the Upregulation of hsa-miR-590.

Authors:  Chia-Chang Wu; Yuan-Hung Wang; Su-Wei Hu; Wen-Ling Wu; Chi-Tai Yeh; Oluwaseun Adebayo Bamodu
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

6.  CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer.

Authors:  Tobias Jagomast; Christian Idel; Luise Klapper; Patrick Kuppler; Anne Offermann; Eva Dreyer; Karl-Ludwig Bruchhage; Julika Ribbat-Idel; Sven Perner
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

7.  Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Authors:  Niklas Klümper; Isabella Syring; Wenzel Vogel; Doris Schmidt; Stefan C Müller; Jörg Ellinger; David Adler; Johannes Brägelmann; Sven Perner
Journal:  Front Med (Lausanne)       Date:  2017-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.